At present, PD-1/PD-L1 monoclonal antibodies have made breakthroughs in clinical trials for the treatment of non-small cell lung cancer, which further indicates that PD-1 and its ligands play an important role in anti-cancer therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.